ÂÜÀòÂÒÂ×

Jon Wigginton, MD has a diverse and extensive work experience in the field of biopharmaceuticals and clinical development. Jon is currently the President of Research and Development at Bright Peak Therapeutics, where they oversee all R&D functions related to the development of novel cytokine-based therapeutics for cancer and autoimmune diseases. Jon also serves as a Member of the Board of Directors at Sutro Biopharma, Inc.

In 2020, Dr. Wigginton founded Bethesda Biomedical Consulting, Inc. where they served as the Founder and President. Jon also held the positions of Chairman SAB and Senior Advisor at Cullinan Oncology during May 2021 to August 2022. Prior to that, they were the Portfolio Chief Medical Officer at Cullinan Oncology from April 2020 to May 2021.

Dr. Wigginton has a significant background in clinical development, having worked as the Chief Medical Officer and Senior Vice-President at MacroGenics, Inc. from 2013 to 2020. During their time there, they led clinical development programs across various therapeutic areas including immuno-oncology/oncology, autoimmune disorders, and infectious diseases. Jon was involved in the development of multiple assets and combination immunotherapy regimens.

Before joining MacroGenics, Dr. Wigginton worked at Bristol-Myers Squibb, where they held several roles, including Therapeutic Area Head of Early Clinical Development, Immuno-Oncology, and Executive Medical Director of Discovery Medicine-Clinical Oncology.

Earlier in their career, Dr. Wigginton served as the President, Vice-President, and Immediate Past-President at the Society for Immunotherapy of Cancer (SITC), a prominent international scientific organization focused on immuno-oncology. Jon has also worked at Merck as the Director of Clinical Oncology and at the National Cancer Institute (NCI) as the Head of the Investigational Biologics Section.

Overall, Dr. Jon Wigginton brings a wealth of expertise and leadership experience in the development of novel therapeutics and clinical research in the field of oncology and autoimmune diseases.

Jon Wigginton, MD has a Bachelor of Science degree in Biology from the University of Michigan. Jon then attended the University of Michigan Medical School, where they earned their Doctor of Medicine (M.D.) degree. Following this, they completed an internship in Internal Medicine-Pediatrics, a residency in Pediatrics, and a fellowship in Pediatric Hematology-Oncology, all of which were also at the University of Michigan Medical School.